

From: [Jarvis, Candace](#)
To: [James L'Italien, PhD \(jlitalien@avexis.com\)](#)
Cc: [Nancy Boman](#); [Jarvis, Candace](#); [Byrnes, Andrew](#); [Thompson, Deborah](#)
Subject: BLA 125694/0| AveXis, Inc | Information Request 16 (PLEASE RESPOND BY JANUARY 8, 2019)
Date: Friday, December 14, 2018 1:38:49 PM
Attachments: [image013.png](#) **Importance:** High

Good afternoon Dr. L'Italien,

We have the following request for information for BLA 125694/0.

The study protocol for AVXS-101-RG-001 indicates that local vascular necrosis is an adverse event of special interest. Please provide background information and data to explain why this is an adverse event of special interest. Please provide this information by January 8, 2019.

Please acknowledge receipt.

Regards,

Candace N. Jarvis
Regulatory Project Manager
Center for Biologics Evaluation and Research
Office of Tissues and Advanced Therapies
U.S. Food and Drug Administration
Tel: 240-402-8315
candace.jarvis@fda.hhs.gov



THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.